Non–muscle-invasive bladder cancer (NMIBC) represents approximately 75% of newly diagnosed bladder cancer cases and carries a high risk of recurrence and progression despite standard intravesical Bacillus Calmette-Guérin (BCG) therapy (1). Patients with high-risk disease—including those with carcinoma in situ (CIS) or T1 lesions face significant un

Hello, and a warm welcome to MedX, where we bring you the latest news and insights from the world of medicine.  FDA Approves Zopapogene Imadenovec for Recurrent Respiratory Papillomatosis The FDA has approved zopapogene imadenovec, a novel adenoviral vector-based immunotherapy, for adult patients with recurrent respiratory papillomatosis. This rare

Introduction: Bladder cancer is the ninth most common malignancy worldwide, with nearly 75% of cases presenting as non-muscle-invasive bladder cancer (NMIBC) (1). Among these, high-risk NMIBC including high-grade Ta (Non-invasive papillary carcinoma), T1 (tumor invades the lamina propria), and CIS (carcinoma in situ) carry a significant risk of rec

Introduction Capmatinib, a highly selective MET inhibitor, in a patient with advanced non-small-cell lung cancer (NSCLC) harboring a MET exon 14 skipping mutation (1). It underscores the importance of molecular profiling in guiding targeted therapy and demonstrates capmatinib's rapid and durable efficacy, consistent with findings from the GEOMETRY

Introduction Capmatinib, a highly potent and selective MET receptor inhibitor, has demonstrated significant antitumor activity in patients with advanced non-small-cell lung cancer (NSCLC) who have MET exon 14 skipping mutations or MET amplification (1). This synopsis highlights key findings from the GEOMETRY mono-1 study, a pivotal phase 2 trial, u

Background Prostate cancer is the most commonly diagnosed malignancy among men, with advanced stages presenting significant therapeutic challenges. Metastatic castration-resistant prostate cancer (mCRPC) represents a particularly aggressive and treatment-refractory disease state, often characterized by disease progression despite androgen deprivati

Background Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are a heterogeneous group of rare neoplasms that arise from neuroendocrine cells within the gastrointestinal tract and pancreas. They are categorized by anatomical origin foregut, midgut, and hindgut as well as tumor grade (G1–G3). Most GEP-NETs express somatostatin receptors (SSTRs

Introduction: Hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) is the most common subtype in postmenopausal women (1). Endocrine therapy, especially aromatase inhibitors (AIs), is the standard first-line treatment due to its effectiveness and tolerability (1). However, resistanc

Introduction More than 70% of breast cancers are hormone receptor (HR)–positive and human epidermal growth factor receptor 2 (HER2)–negative, with approximately 40% harboring activating phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) mutations that hyperactivate the alpha (α) isoform of phosphatidylinositol 3-kinase